Clinically, GLP-1s show potential beyond diabetes and obesitythere's promise in areas like sleep apnea and cardiovascular conditions, he explained
Ask what diagnosis is being treated, what evidence supports the option, whether imaging or rehabilitation is needed, whether the source is legitimate, what risks apply to your health history, how progress will be measured, and what the plan is if symptoms do not improve
These chemicals are not only mood boosters, they also: Reduce inflammatory signaling Regulate overactive immune responses Support tissue healing and stress resilience In short, LDN helps bring the body back into balance, especially if chronic inflammation or immune dysfunction is part of the picture
At the 12-month follow-up : 87.5% of patients reported significant relief defined as 50% reduction in baseline pain scores Mean VAS pain score dropped from 7.2 at baseline to 2.8 at 12 months KOOS (Knee Injury and Osteoarthritis Outcome Score) improved across all subscales: pain, symptoms, activities of daily living, sport/recreation, and quality of life No serious adverse events were reported across the treatment period The durability of the response at 12 months is particularly notable
Funding This study was sponsored by Eli Lilly
Try to focus on the positive step you are taking for your health